文献速递消化、代谢与肾脏急症

阿司匹林与肝细胞癌及肝病相关死亡的关系

Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.
PubMed 文献 · N Engl J Med · 2020-01-01
一句话结论在瑞典全国性慢性乙型或丙型肝炎患者中,低剂量阿司匹林使用与肝细胞癌发生风险和肝病相关死亡率显著降低相关,且未显著增加消化道出血风险。

该研究利用瑞典全国登记数据,纳入2005至2015年诊断慢性乙型或丙型肝炎且无阿司匹林使用史的成年患者,比较开始使用低剂量阿司匹林(≤160 mg)者与未使用者。通过倾向评分逆概率加权和Cox回归分析,中位随访7.9年,阿司匹林使用者肝细胞癌累积发生率4.0% vs 未使用者8.3%(差值-4.3个百分点,95%CI -5.0至-3.6;校正HR 0.69,95%CI 0.62-0.76),肝病相关10年死亡率11.0% vs 17.9%(差值-6.9个百分点,95%CI -8.1至-5.7;校正HR 0.73,95%CI 0.67-0.81)。消化道出血10年风险两组无显著差异(7.8% vs 6.9%,差值0.9个百分点,95%CI -0.6至2.4)。

要点

  • 在慢性乙型或丙型肝炎患者中,低剂量阿司匹林(≤160 mg)使用与肝细胞癌风险降低相关(校正HR 0.69,95%CI 0.62-0.76)。
  • 低剂量阿司匹林使用与肝病相关10年死亡率降低相关(11.0% vs 17.9%;校正HR 0.73,95%CI 0.67-0.81)。
  • 肝细胞癌风险降低似乎呈持续时间依赖性,使用5年及以上者校正HR 0.57(95%CI 0.42-0.70)。
  • 低剂量阿司匹林使用者与未使用者10年消化道出血风险无显著差异(7.8% vs 6.9%;差值0.9个百分点,95%CI -0.6至2.4)。

适用人群与场景

  • 2005至2015年在瑞典被诊断为慢性乙型或丙型肝炎的成年患者,且无阿司匹林使用史(50,275例)。
  • 阿司匹林使用者定义为首次开具连续90剂或以上低剂量阿司匹林处方者(14,205例)。

研究设计与关键结果

  • 研究类型:基于瑞典全国登记数据的队列研究,采用倾向评分逆概率治疗加权和Cox比例风险回归模型,中位随访7.9年。
  • 主要终点肝细胞癌累积发生率:阿司匹林使用者4.0% vs 未使用者8.3%(差值-4.3个百分点,95%CI -5.0至-3.6;校正HR 0.69,95%CI 0.62-0.76)。
  • 肝细胞癌风险与使用时长相关:与短期使用(3个月至<1年)相比,使用1至<3年校正HR 0.90(95%CI 0.76-1.06),3至<5年校正HR 0.66(95%CI 0.56-0.78),5年及以上校正HR 0.57(95%CI 0.42-0.70)。
  • 肝病相关10年死亡率:阿司匹林使用者11.0% vs 未使用者17.9%(差值-6.9个百分点,95%CI -8.1至-5.7;校正HR 0.73,95%CI 0.67-0.81)。
  • 10年消化道出血风险:阿司匹林使用者7.8% vs 未使用者6.9%(差值0.9个百分点,95%CI -0.6至2.4),两组无显著差异。

证据类型、等级与局限

  • 证据类型:基于全国登记数据的观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为,在慢性病毒性肝炎患者中,低剂量阿司匹林使用与肝细胞癌风险及肝病相关死亡率降低相关,且未显著增加消化道出血风险。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

METHODS: Using nationwide Swedish registries, we identified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 2015 and who did not have a history of aspirin use (50,275 patients). Patients who were starting to take low-dose aspirin (14,205 patients) were identified by their first filled prescriptions for 90 or more consecutive doses of aspirin. We constructed a propensity score and applied inverse probability of treatment weighting to balance baseline characteristics between groups. Using Cox proportional-hazards regression modeling, we estimated the risk of hepatocellular carcinoma and liver-related mortality, accounting for competing events.

RESULTS: With a median of 7.9 years of follow-up, the estimated cumulative incidence of hepatocellular carcinoma was 4.0% among aspirin users and 8.3% among nonusers of aspirin (difference, -4.3 percentage points; 95% confidence interval [CI], -5.0 to -3.6; adjusted hazard ratio, 0.69; 95% CI, 0.62 to 0.76). This inverse association appeared to be duration-dependent; as compared with short-term use (3 months to <1 year), the adjusted hazard ratios were 0.90 (95% CI, 0.76 to 1.06) for 1 to less than 3 years of use, 0.66 (95% CI, 0.56 to 0.78) for 3 to less than 5 years of use, and 0.57 (95% CI, 0.42 to 0.70) for 5 or more years of use. Ten-year liver-related mortality was 11.0% among aspirin users and 17.9% among nonusers (difference, -6.9 percentage points [95% CI, -8.1 to -5.7]; adjusted hazard ratio, 0.73 [95% CI, 0.67 to 0.81]). However, the 10-year risk of gastrointestinal bleeding did not differ significantly between users and nonusers of aspirin (7.8% and 6.9%, respectively; difference, 0.9 percentage points; 95% CI, -0.6 to 2.4).

CONCLUSIONS: In a nationwide study of patients with chronic viral hepatitis in Sweden, use of low-dose aspirin was associated with a significantly lower risk of hepatocellular carcinoma and lower liver-related mortality than no use of aspirin, without a significantly higher risk of gastrointestinal bleeding. (Funded by the National Institutes of Health and others.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Simon TG, Duberg AS, Aleman S, et al. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. N Engl J Med. 2020. PMID: 32160663. doi:10.1056/NEJMoa1912035

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。